The news comes following the FDA ... Imuldosa is a biosimilar to Stelara, a blockbuster drug developed by Janssen Biotech for ...

US FDA approves UCB’s 320 mg single-injection device presentations of Bimzelx: Brussels, Belgium Tuesday, October 15, 2024, 13:00 Hrs [IST] UCB, a global biopharmaceutical compa ...

Researchers from Oregon Health & Science University and institutions across the country have identified a pill used to treat ...

A new oral treatment for psoriatic arthritis, Celgene's Otezla ... Celgene's extensive trial programme showed the drug provided benefits comparable to those seen in patients taking TNF blocker ...

In the phase 4 FOREMOST trial, treatment with apremilast improved both clinical and patient-reported outcomes at week 16 among patients with early oligoarticular PsA.

Bimzelx is now approved for the treatment of adult patients with psoriatic arthritis ... Drug Administration (FDA) has expanded the approval of Bimzelx ® (bimekizumab-bkzx) to include 3 new ...

Imuldose will be marketed in the United States by Accord BioPharma and is expected to launch in the first half of 2025.

FDA Approvals, September 23, 2013 Alert CHMP Says Yes to New Indication for Ustekinumab The committee recommends approval of the drug for the treatment of active psoriatic arthritis in adults who ...

Symptoms of psoriatic arthritis are similar to rheumatoid arthritis and include, pain, swelling and stiffness in one or more ...

Targeted therapies for PsA are effective for reducing the use of symptomatic treatments, sick leave, and rates of hospitalization.

As we observe World Arthritis Day on October 12, it's crucial to raise awareness about this prevalent condition that affects ...

Medscape Medical News, June 19, 2024 EULAR 2024 Psoriatic Arthritis Drugs Comparably Improve Joint Outcomes Real-world study data suggest there is little difference among five drug classes ...